BR112018009281A8 - composições para tratar atrofia muscular espinhal - Google Patents

composições para tratar atrofia muscular espinhal

Info

Publication number
BR112018009281A8
BR112018009281A8 BR112018009281A BR112018009281A BR112018009281A8 BR 112018009281 A8 BR112018009281 A8 BR 112018009281A8 BR 112018009281 A BR112018009281 A BR 112018009281A BR 112018009281 A BR112018009281 A BR 112018009281A BR 112018009281 A8 BR112018009281 A8 BR 112018009281A8
Authority
BR
Brazil
Prior art keywords
compositions
muscular atrophy
spinal muscular
treating spinal
compound
Prior art date
Application number
BR112018009281A
Other languages
English (en)
Other versions
BR112018009281B1 (pt
BR112018009281A2 (pt
Inventor
Paulo Morawski Vianna Eduardo
Metzger Friedrich
Alsenz Jochem
Dorothy MCCARTHY Kathleen
Lloyd Woodhouse Marvin
Grassmann Olaf
Kuehl Peter
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of BR112018009281A2 publication Critical patent/BR112018009281A2/pt
Publication of BR112018009281A8 publication Critical patent/BR112018009281A8/pt
Publication of BR112018009281B1 publication Critical patent/BR112018009281B1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

a presente invenção oferece composições farmacêuticas compreendendo um composto de fórmula (i) (i) onde a, r1, r2 e r3 são como descritos neste pedido, assim como sais farmaceuticamente aceitáveis do mesmo. ademais, a presente invenção refere-se à produção das composições farmacêuticas compreendendo um composto de fórmula (i) e seu uso como medicamentos.
BR112018009281-9A 2015-11-12 2016-11-08 Composições para tratar atrofia muscular espinhal e seu uso BR112018009281B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP15194297 2015-11-12
EP15194297.6 2015-11-12
PCT/EP2016/076905 WO2017080967A1 (en) 2015-11-12 2016-11-08 Compositions for treating spinal muscular atrophy

Publications (3)

Publication Number Publication Date
BR112018009281A2 BR112018009281A2 (pt) 2018-11-06
BR112018009281A8 true BR112018009281A8 (pt) 2019-02-26
BR112018009281B1 BR112018009281B1 (pt) 2023-10-31

Family

ID=54542056

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112018009281-9A BR112018009281B1 (pt) 2015-11-12 2016-11-08 Composições para tratar atrofia muscular espinhal e seu uso

Country Status (14)

Country Link
US (2) US20180289712A1 (pt)
EP (2) EP3373972B1 (pt)
JP (1) JP6659841B2 (pt)
KR (1) KR102162062B1 (pt)
CN (1) CN108289959B (pt)
AR (1) AR106717A1 (pt)
AU (1) AU2016353961B2 (pt)
BR (1) BR112018009281B1 (pt)
CA (1) CA3002494C (pt)
EA (1) EA036399B1 (pt)
HK (1) HK1256089A1 (pt)
IL (1) IL258497B (pt)
MX (1) MX2018005890A (pt)
WO (1) WO2017080967A1 (pt)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102256013B1 (ko) 2014-05-15 2021-05-26 에프. 호프만-라 로슈 아게 척수성 근위축증을 치료하기 위한 화합물
US10882868B2 (en) 2014-05-15 2021-01-05 Hoffmann-La Roche Inc. Compounds for treating spinal muscular atrophy
EP3373972B1 (en) 2015-11-12 2024-03-20 F. Hoffmann-La Roche AG Compositions for treating spinal muscular atrophy
JP6872550B2 (ja) 2015-12-10 2021-05-19 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 架橋されたピペリジン誘導体
WO2017100726A1 (en) 2015-12-10 2017-06-15 Ptc Therapeutics, Inc. Methods for treatng huntington's disease
WO2018073141A1 (en) * 2016-10-18 2018-04-26 F. Hoffmann-La Roche Ag New composition for treating sma
EP3634953B1 (en) 2017-06-05 2024-01-03 PTC Therapeutics, Inc. Compounds for treating huntington's disease
CA3067592A1 (en) 2017-06-28 2019-01-03 Ptc Therapeutics, Inc. Methods for treating huntington's disease
CN111182898B (zh) 2017-06-28 2024-04-16 Ptc医疗公司 用于治疗亨廷顿氏病的方法
EP3661509A4 (en) 2017-08-04 2021-01-13 Skyhawk Therapeutics, Inc. METHODS AND COMPOSITIONS FOR MODULATING THE SPLICE
WO2019057740A1 (en) * 2017-09-22 2019-03-28 F. Hoffmann-La Roche Ag PROCESS FOR THE PREPARATION OF 7- (4,7-DIAZASPIRO [2.5] OCTAN-7-YL) -2- (2,8-DIMETHYLIMIDAZO [1,2-B] PYRIDAZIN-6-YL) PYRIDO [1,2-DERIVATIVES] ] pyrimidin-4-ONE
CA3078137A1 (en) * 2017-10-03 2019-04-11 F. Hoffmann-La Roche Ag New treatment of sma
AU2019243048A1 (en) 2018-03-27 2020-10-15 Ptc Therapeutics, Inc. Compounds for treating Huntington's disease
WO2020005873A1 (en) 2018-06-27 2020-01-02 Ptc Therapeutics, Inc. Heterocyclic and heteroaryl compounds for treating huntington's disease
US11685746B2 (en) 2018-06-27 2023-06-27 Ptc Therapeutics, Inc. Heteroaryl compounds for treating Huntington's disease
JOP20200338A1 (ar) * 2018-06-27 2020-12-24 Reborna Biosciences Inc عامل وقائي أو علاجي للضمور العضلي نخاعي المنشأ
KR20210079317A (ko) * 2018-10-19 2021-06-29 에프. 호프만-라 로슈 아게 피리도[1,2-a]피리미딘-4-온 유도체의 형태, 그의 제형 및 그의 제조 방법
WO2020163405A1 (en) 2019-02-05 2020-08-13 Skyhawk Therapeutics, Inc. Methods and compositions for modulating splicing
KR20210135507A (ko) 2019-02-06 2021-11-15 스카이호크 테라퓨틱스, 인코포레이티드 스플라이싱을 조절하는 방법 및 조성물
CN113966219A (zh) 2019-06-12 2022-01-21 豪夫迈·罗氏有限公司 Sma的新治疗方法
JP2022544538A (ja) * 2019-08-15 2022-10-19 バイオジェン・エムエイ・インコーポレイテッド 脊髄性筋萎縮症のための併用療法
WO2023057404A1 (en) 2021-10-06 2023-04-13 F. Hoffmann-La Roche Ag Novel combined administration
WO2023202501A1 (zh) * 2022-04-18 2023-10-26 深圳市塔吉瑞生物医药有限公司 取代的吡啶并嘧啶酮类化合物及包含该化合物的组合物及其用途

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1383409A (en) 1972-09-09 1974-02-12 Pfizer Ltd Derivatives of 2-amino- and 4-amino-quinazoline and pharmaceutical compositions containing them
US6774134B2 (en) 2000-12-20 2004-08-10 Bristol-Myers Squibb Company Heterocyclic substituted 2-methyl-benzimidazole antiviral agents
DK1601363T3 (da) 2003-03-11 2012-09-03 Trophos Anvendelse som lægemiddel af derivater af cholest-4-en-3-on, farmaceutiske sammensætninger indeholdende disse og nye derivater
WO2005061513A1 (en) 2003-12-24 2005-07-07 Biota Scientific Management Pty Ltd Polycyclic agents for the treatment of respiratory syncytial virus infections
US20060153920A1 (en) 2004-09-24 2006-07-13 Ketan Amin Lyophilized pharmaceutical compositions
FR2914188B1 (fr) 2007-03-28 2012-06-22 Trophos Nouvelle composition a base d'oxime de cholest-4-en-3-one
US8633019B2 (en) 2008-05-27 2014-01-21 Ptc Therapeutics, Inc. Methods for treating spinal muscular atrophy
WO2010019236A1 (en) 2008-08-13 2010-02-18 Ptc Therapeutics, Inc Methods for treating spinal muscular atrophy
WO2010019326A1 (en) 2008-08-14 2010-02-18 Cardiac Pacemakers, Inc. Performance assessment and adaptation of an acoustic communication link
EP2359812A1 (en) 2010-01-18 2011-08-24 Cephalon France Oral lyophilised compositions
US8703763B2 (en) 2011-03-02 2014-04-22 Hoffmann-La Roche Inc. Bridged piperidine derivatives
US8871756B2 (en) 2011-08-11 2014-10-28 Hoffmann-La Roche Inc. Compounds for the treatment and prophylaxis of Respiratory Syncytial Virus disease
GB201119538D0 (en) 2011-11-10 2011-12-21 Viral Ltd Pharmaceutical compounds
US9617268B2 (en) 2011-12-30 2017-04-11 Ptc Therapeutics, Inc. Compounds for treating spinal muscular atrophy
US9399649B2 (en) * 2012-01-26 2016-07-26 Ptc Therapeutics, Inc. Compounds for treating spinal muscular atrophy
CN108299314A (zh) * 2012-02-10 2018-07-20 Ptc医疗公司 用于治疗脊髓性肌萎缩的化合物
CA2878895A1 (en) 2012-07-13 2014-01-16 Indiana University Research & Technology Corporation Compounds for treatment of spinal muscular atrophy
MX2015015691A (es) 2013-05-14 2016-03-04 Hoffmann La Roche Aza-oxo-indoles novedosos para el tratamiento y profilaxis de la infeccion del virus sincital respiratorio.
BR112015030288B1 (pt) 2013-06-25 2022-10-18 Ptc Therapeutics, Inc. Compostos e seu uso no tratamento de atrofia muscular espinhal
AR099134A1 (es) 2014-01-24 2016-06-29 Hoffmann La Roche Procedimiento para la preparación de n-[(3-aminooxetán-3-il)metil]-2-(1,1-dioxo-3,5-dihidro-1,4-benzotiazepín-4-il)-6-metil-quinazolín-4-amina
KR102256013B1 (ko) * 2014-05-15 2021-05-26 에프. 호프만-라 로슈 아게 척수성 근위축증을 치료하기 위한 화합물
EP3373972B1 (en) 2015-11-12 2024-03-20 F. Hoffmann-La Roche AG Compositions for treating spinal muscular atrophy

Also Published As

Publication number Publication date
AR106717A1 (es) 2018-02-14
IL258497A (en) 2018-06-28
EP4360707A2 (en) 2024-05-01
KR20180080317A (ko) 2018-07-11
CA3002494C (en) 2021-01-12
US20180289712A1 (en) 2018-10-11
IL258497B (en) 2021-07-29
EP3373972B1 (en) 2024-03-20
EA036399B1 (ru) 2020-11-06
US20200323856A1 (en) 2020-10-15
CN108289959B (zh) 2021-07-16
KR102162062B1 (ko) 2020-10-07
CN108289959A (zh) 2018-07-17
CA3002494A1 (en) 2017-05-18
JP2018533605A (ja) 2018-11-15
AU2016353961A1 (en) 2018-04-26
WO2017080967A1 (en) 2017-05-18
EA201891103A1 (ru) 2018-11-30
JP6659841B2 (ja) 2020-03-04
US11938136B2 (en) 2024-03-26
EP3373972C0 (en) 2024-03-20
MX2018005890A (es) 2018-08-15
BR112018009281B1 (pt) 2023-10-31
HK1256089A1 (zh) 2019-09-13
EP3373972A1 (en) 2018-09-19
BR112018009281A2 (pt) 2018-11-06
AU2016353961B2 (en) 2019-08-29

Similar Documents

Publication Publication Date Title
BR112018009281A2 (pt) composições para tratar atrofia muscular espinhal
CR20160518A (es) Compuestos para tratar atrofia muscular espinal
CY1122046T1 (el) Δικυκλικα ετεροκυκλικα παραγωγα ως αναστολεις βρομοτομεων
CO2017013708A2 (es) Macrociclos peptídicos contra acinetobacter baumannii.
BR112018071216A2 (pt) inibidores de bromodomínios
CO2018004857A2 (es) Derivados de dihidroimidazopirazinona usados en el tratamiento del cáncer
BR112014018990A8 (pt) Derivados de ácido benzotiazol-6-il acético e seu uso para tratamento de uma infecção
MX2015017345A (es) Compuestos para tratar atrofia muscular espinal.
BR112018070123A2 (pt) oxiesterós e métodos de uso dos mesmos
BR112016017996A2 (pt) 6-heteroariloxi- or 6-ariloxi-quinolina-2-carboxamidas e método de uso
BR112018003827A2 (pt) composto, composição farmacêutica, combinação, uso de um composto, e, método para tratamento de uma doença ou condição.
TW201613864A (en) Novel compounds
CY1122077T1 (el) Νεα δακτυλιωμενα φαινοξυακεταμιδια
PH12017501280A1 (en) Hydroxyalkyl-piperazine derivatives as cxcr3 receptor modulators
CL2021001388A1 (es) Compuestos útiles en la terapia para el vih
BR112017019653A2 (pt) derivados heteroaril bicíclicos fundidos tendo atividade como inibidores de phd
DOP2018000049A (es) Compuestos para uso en aplicaciones antibacterianas
EA201700356A1 (ru) Новые циклопропанбензофуранилпиридопиразиндионы
BR112017021083A2 (pt) piridopirimidinonas e seu uso como moduladores do receptor de nmda
EA202090978A1 (ru) Новые макроциклические производные, способ их получения и содержащие их фармацевтические композиции
BR112019007631A2 (pt) inibidores de bromodomínios
EA201891319A1 (ru) Соединения алкилдигидрохинолинсульфонамида
BR112015003998A2 (pt) compostos de cianopirazol lpar-substituídos
BR112018003181A2 (pt) composto, composição, e, método para tratar infecção por hiv
BR112022005728A2 (pt) Compostos de tiazol carboxamida e seu uso para o tratamento de infecções micobacterianas

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 08/11/2016, OBSERVADAS AS CONDICOES LEGAIS